Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
QoL · schizophrenia
1 finding from 1 review
Social functioning · schizophrenia
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Cognitive function: average endpoint score** · adults with schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · people with both severe mental illness and substance misuse
1 finding from 1 review
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · people with both severe mental illness and substance misuse
1 finding from 1 review
Mental state: 1. Mean change PANSS positive subscale (lower value = good) · patients with schizophrenia
1 finding from 1 review
Mental state: 2. Mean change PANSS negative subscale (lower value = good) · patients with schizophrenia
1 finding from 1 review
QoL · patients with schizophrenia
1 finding from 1 review
Well‐being and quality of life Personal Wellbeing Index (PWI‐C) . Scale from: 0 to 77 (low = poor) · patients with schizophrenia
It is very uncertain whether horticultural therapy plus standard care changes well‐being and quality of life Personal Wellbeing Index (PWI‐C) .… compared with standard care alone (very low certainty).
1 finding from 1 review
Drop in the absolute neutrophil count below 1500 per mm3 · people with psychosis
1 finding from 1 review
Intervention not reported
Global effect: 1a. Medium‐term ‐ Average end point score on various outcomes ‐ CGI‐severity (low = favourable) ( · schizophrenia
1 finding from 1 review
Intervention not reported
Mental state: 1b. Average end point score on various outcomes‐PANSS (medium‐term) ‐ Medium‐term ‐ PANSS negative end point score (low = favourable) · schizophrenia
1 finding from 1 review
Intervention not reported
Mental state: 1b.Average end point score on various outcomes‐PANSS (medium‐term) ‐ Medium term ‐ PANSS general psychopathology end point score (low = favourable) · schizophrenia
1 finding from 1 review
Intervention not reported
Adverse event: 11a. Short‐term ‐ Average end point score on EPSEs scale (low = favourable) ‐ AIMS · schizophrenia
1 finding from 1 review